The large scale antibacterial, antifungal and anti-phage efficiency of Petamcin-A: new multicomponent preparation for skin diseases treatment by unknown
Ginovyan et al. Annals of Clinical Microbiology and Antimicrobials  (2015) 14:28 
DOI 10.1186/s12941-015-0087-zRESEARCH Open AccessThe large scale antibacterial, antifungal and
anti-phage efficiency of Petamcin-A: new
multicomponent preparation for skin
diseases treatment
Mikayel Ginovyan1, Andranik Keryan1, Inga Bazukyan1, Petros Ghazaryan2 and Armen Trchounian1*Abstract
Background: Human and animal skin diseases of bacterial, fungal and viral nature and their complications are
widespread and globally cause a serious trouble. Their prevalence is increasing mainly due to drug resistance.
Consequently, demand has increased for new effective antimicrobial drugs, which also should be less toxic,
possess a wider spectrum of action and be economically more beneficial. The goal was to investigate antibacterial,
antifungal and anti-phage activity of Petamcin-A-a new multicomponent preparation. It contains acetic acid and
hexamethylenetetramine as main active antimicrobial components, as well as phosphatidylcholine, tocopheryl
acetate and glycerol as excipients.
Methods: Bacteriostatic activity and minimal inhibitory concentrations of the preparation against various test-organisms
were determined by agar well diffusion assay. Antifungal activity was tested by agar dilution assay. To explore anti-phage
activity double agar overlay plaque assay was used. Nystatin, chlorhexidine and acetic acid were used as control agents
for comparative analysis. Statistical analysis was done with GraphPad Prism 5.03 or R 3.1.0 software.
Results: The results showed a higher activity of Petamcin-A against all bacterial and fungal test strains compared
with its components or control agents. The preparation was more effective against tested gram-positive bacteria than
gram-negative ones. Petamcin-A expressed bactericidal activity against almost all test strains. In addition, the preparation
demonstrated high activity against T4 phage of Escherichia coli C-T4 completely inhibiting its growth. 5-fold diluted
Petamcin-A also exhibited considerable activity reducing phage concentration by 2.6 Log10.
Conclusions: Petamcin-A has a high antimicrobial activity against all tested strains of bacteria, yeasts and moulds.
The preparation also exhibited high anti-phage activity. Moreover, taking into account that Petamcin-A has no
observable toxicity on skin and its components are not expensive, it can be advantageous for management of
various skin medical conditions.
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The prevalence of bacterial, fungal and viral skin infec-
tious diseases and their complications are continuously in-
creasing throughout the world. Because of the limited
number of therapeutic methods this problem is one of the
most urgent challenges in biology and medicine [1–3].
The frequency of these diseases is particularly higher in
developing countries, mainly due to lower level of their
healthcare systems as well as inability of many patients to
receive expensive treatment for a long period of time [4].
Treatment difficulties of these diseases mainly are a conse-
quence of acquired resistance development by microor-
ganisms towards commonly used drugs [5–8]. Therefore,
it is not a coincidence, that 21th century is considered as
post-antibiotic era in order to highlight importance of the
problem [9]. Another serious challenge of the field is the
acquisition of pathogenicity by microorganisms previously
considered as non-pathogenic, which could happen due to
various mutations, increasing number of immune-
compromised patients, etc. [10]. Hence, the development
of new, more efficient drugs is of utmost importance. On
the other hand, it is essential to create economically more
beneficial antimicrobials affordable for a population living
in poor regions. Another criterion of new antimicrobials is
a wide spectrum of action, considering the fact that many
skin infections are caused by various microbial associa-
tions [11].
Both topical and systemic antimicrobial agents could
be used for treatment of skin infections depending on
various conditions (infection stage, size of infected area,
type of pathogens, depth of infections, etc.). Both of
them have their advantages and disadvantages [12, 13].
Particularly, topical antimicrobials help to avoid systemic
toxicity and side effects as well as to decrease the possibil-
ity of resistance acquisition. Moreover, they allow to apply
high concentration of antimicrobials directly on the zone
of infection. The main disadvantage of topical agents is a
difficulty to supply active agents to affected area, especially
during deep skin infections [12, 13].
The object of this study was the multi-component liquid
preparation Petamcin-A, which was developed and pat-
ented as topical antifungal agent [14]. Preparation contains
acetic acid, hexamethylenetetramine, phosphatidylcholine,
tocopheryl acetate and glycerol [14]. It has been success-
fully used during recent years for treatment of skin fungal
diseases. This preparation does not have any noticeable tox-
icity and does not express any side effects [14, 15]. Accord-
ing to the preliminary data, under the influence of this
preparation, statistically significant normalization of cyto-
toxic and membranolytic lysophosphatides and phospholip-
ase A2 activity are observed at experimental animals [15].
This testifies about Petamin-A’s membrane stabilizing prop-
erties. The preparation also expresses antioxidant activity
which is partially connected with its phosphatidylcholineand tocopheryl acetate components [14]. As it was shown,
the preparation promotes fast purification of the leukocytic
and necrotic mass of the wound, suppresses the activity of
inflammatory reactions, stimulates cellular proliferation,
and promotes the growth of connective tissue and regener-
ation of wound epithelium [15].
Two components of Petamcin-A-acetic acid and hexa-
methylenetetramine are responsible for its antimicrobial
activity. Apart from antifungal activity, these compounds
also possess antibacterial and antiviral activity and separ-
ately have been used for some applications [16, 17].
The main purpose of this study was to investigate
antibacterial, antifungal and anti-phage properties of
Petamcin-A. The obtained results could serve as a basis
to develop its production for skin diseases treatment.
Materials and Methods
Microorganisms, growth conditions and antimicrobials used
Following microorganisms were used as test strains:
bacteria Escherichia coli VKPM-M17 (Russian National
Collection of Industrial Microorganisms at the Institute
of Genetics and Selection of Industrial Microorganisms,
Russia) (Laboratory control strain), Pseudomonas aeru-
ginosa GRP3 (Soil and Water Research Institute, Iran)
(Laboratory control strain), Bacillus subtilis WT-A1, iso-
lated from metal polluted soils of Kajaran, Armenia, and
Bacillus licheniformis WT (Department of Microbiology,
Plants and Microbes Biotechnology, Yerevan State Uni-
versity (YSU), Armenia) (Laboratory control strains),
Micrococcus luteus WT (Department of Microbiology,
Plants and Microbes Biotechnology, YSU, Armenia)
(Laboratory control strain), Salmonella typhimurium
MDC 1754 (Microbial Depository Center, Armbiotechnol-
ogy Scientific and Production Center, Armenia) (Labora-
tory control strain), Staphylococcus aureus MDC 5233
(Microbial Depository Center, Armbiotechnology Scientific
and Production Center, Armenia) (Laboratory control
strain), Lactobacillus delbrueckii subsp. lactis INRA-2010-
4.2 (Department of Microbiology, Plants and Microbes
Biotechnology, YSU, Armenia) (Probiotic strain), Lacto-
bacillus delbrueckii subsp. bulgaricus INRA-2010-5.2
(Department of Microbiology, Plants and Microbes Bio-
technology, YSU, Armenia) (Probiotic strain), Escherichia
coli C-T4 (Eliava Institute of Bacteriophage, Microbiology
and Virology, Georgia), yeasts Candida albicans WT-174
isolated from infected vaginal microbiota of hospitalized
patients (Department of Botany and Mycology, YSU,
Armenia) (Clinical strain), Candida guilliermondii HP-17
(Department of Botany and Mycology, YSU Armenia)
(Laboratory control strain), Debaryomyces hansenii WT
(French National Institute for Agricultural Research
(INRA), France) (Laboratory control strain), mould Mucor
plumbeus WT and Geotrichum candidum WT (INRA,
France) (Food pathogens), Penicillium aurantioviolaceum
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isolated from spoiled food, and Aspergillus flavus WT
isolated from spoiled food (Department of Botany and
Mycology, YSU, Armenia) (Food pathogens).
LB medium was used for cultivation of bacteria (peptone
10 g l−1, yeast extract 5 g l−1, sodium chloride 10 g l−1,
sucrose 5 g l−1, MgSO4 0.5 g l
−1), except Lactobacillus
delbrueckii subsp. lactis and Lactobacillus delbrueckii
subsp. bulgaricus which were cultivated in MRS (HiMedia,
India). Beer wort agar (BWA) (Sigma-Aldrich, USA) and
Sabouraud (glucose 40 g l−1, peptone 10 g l−1, yeast extract
5 g l−1) media were used for cultivation of fungi. To obtain
solid medium, agar (9 g l−1) was added to nutrient media
mentioned above.
12 % v/v acetic acid (one of the active compounds of
Petamcin-A) as well as 30 μg ml−1 concentration of
nystatin (“Borisov Plant of Medical Preparations” JSC,
Borisov, Belarus) dissolved in 5 % DMSO and 0.2 % w/v
chlorhexidine gluconate (“Arsanit” LLC, Yervan, Armenia)
were used as control agents for comparative analysis of
the Petamcin-A activity.
Determination of antibacterial and anti-yeast activity
The bacteriostatic activity of Petamcin-A was tested by
modified agar well diffusion assay [18]. 100 μl of overnight
bacterial suspensions of indicator strains (adjusted to 106
colony-forming unit (CFU) ml−1) were poured into Petri
dishes. Subsequently, 25 ml medium was added on top of
them at 50 °C and gently shaken. After medium solidifica-
tion wells with a diameter of 8 mm were cut in it. 100 μl
of compounds were added into wells. Plates were incu-
bated at 37 °C except for D. hansenii, which was incubated
at 27 °C. After 24 h zones of growth inhibition around the
wells were measured.
For determination of minimal inhibitory concentrations
(MIC) different concentrations of the preparation were
tested by the method described above. The preparation
was diluted in sterile distilled water. The maximal dilution
which caused well defined growth inhibition zone of at
least 2 mm was considered as MIC.
Bactericidal activity was determined by modified broth
macrodilution method [19]. Approximately 1 mm3 parts
of the medium from growth inhibition zones were cut off
and subcultured in a liquid medium without antimicro-
bials. Tubes with media were incubated for 24 h. The
growth of bacteria was estimated by measuring the optical
density (OD) of culture media at 595 nm wavelength light
using a spectrophotometer (GENESYS 10S UV–VIS,
Thermo Scientific, USA). The absence of growth indicated
about bactericidal activity of the preparation.Determination of anti-mould activity
Anti-mould activity of the preparation was explored by
agar dilution assay [18]. BWA plates were inoculated withtest strains and kept at 27 °C for 10 day for complete
spore formation. Then spores were separated from myce-
lia by washing with saline solution and poured into tubes.
The concentration of spores was calculated with hemocyt-
ometer. The preparations were poured into small (5 ml)
Petri dishes in appropriate concentrations, then 2 ml of
BWA medium at 50 °C was added and gently shaken. After
solidification 104 CFU ml−1 fungal spores were added. Petri
dishes were incubated for 10 day at 27 °C. The absence of
growth indicated about anti-mould activity. Different con-
centrations of preparations were used in order to deter-
mine the MICs.
Determination of anti-phage activity
Anti-phage activity was determined by double agar overlay
plaque assay [18]. Firstly, phage suspension was prepared.
The concentration of plaque-forming units (PFU) was
determined by the same method. In experimental group
30 μl of phage suspension at 1011 PFU ml−1 concentration
and 30 μl of tested preparations were poured in a tube,
while in the control group 30 μl saline solution was used
instead of the preparations. The mixtures were incubated
for 90 min at 37 °C. Then phage mixtures were diluted up
to 10−8 in LB broth by serial ten-fold dilutions. E. coli
C-T4 was pre-cultivated on slant agar then washed with
LB broth and transferred into sterile tubes. The concen-
tration of cells was determined measuring OD at 595 nm
wavelength light. Appropriate dilution of phage (in vol-
ume of 1 ml) was poured into a tube. E. coli C-T4 (100 μl)
was added and then 6 ml of LB containing 0.7 % agar at
50 °C was added on top. The mixture was shaken and
poured in Petri dishes containing 20 ml 1.8 % LB agar.
The plates were swirled, left to dry for 10 min at room
temperature and incubated for 24 h at 37 °C. Viable phages
form plaques on the seeded plates which could be enumer-
ated. The number of viable phage particles in stock solu-
tion was determined by multiplying plaque numbers with
dilution factor. The efficiency of the preparations was
determined by comparing the amount of viable phage
particles from experimental and control groups.
Data processing
All experiments were independently repeated three times.
Obtained data were processed; standard deviations and
standard errors were calculated using GraphPad Prism
5.03 (GraphPad Software, Inc.; USA) software. P-values
were determined by Student’s t-test with R 3.1.0 (The R
foundation of statistical computing, Vienna, Austria,
2014) software.
Results
Antimicrobial activity of Petamcin-A against different
test strains was investigated. The obtained data showed
that Petamcin-A has a high antibacterial activity against
Table 1 Antibacterial and anti-yeast activity of Petamcin-A in comparison with 30 μg mlx−1 nystatin, 0.2 % chlorhexidine and 12 %
acetic acida
Test strains Growth inhibition zones, mm
Petamcin-A Chlorhexidine Nystatin Acetic acid
Escherichia coli 34 ± 0.9 21 ± 0.9 0 18 ± 0.5
Pseudomonas aeruginosa 36 ± 1 12 ± 0.7 0 25 ± 0.8
Salmonella typhimurium 44 ± 0.6 24 ± 1 0 31 ± 0.6
Bacillus licheniformis 54 ± 1.5 21 ± 0.6 0 35 ± 0.7
Bacillus subtilis 43 ± 1.2 19 ± 0.5 0 23 ± 0.6
Lactobacillus delbrueckii subsp. lactis 42 ± 1.2 23 ± 0.7 0 22 ± 0.9
Lactobacillus delbrueckii subsp. bulgaricus 41 ± 1 22 ± 1 0 21 ± 0.6
Micrococcus luteus 63 ± 1.5 31 ± 0.11 21 ± 0.9 45 ± 1
Staphylococcus aureus 56 ± 1 20 ± 0.8 0 29 ± 0.9
Candida albicans 31 ± 0.8 25 ± 0.7 27 ± 1 22 ± 0.4
Candida guilliermondii 45 ± 01.1 28 ± 0.9 26 ± 0.8 24 ± 1.1
Debaryomyces hansenii 79 ± 2 40 ± 1.2 32 ± 1.2 35 ± 0.1
aAll experiments were independently repeated three times. Mean values with standard deviations are presented, p ≤ 0.003. For strains and details, see Materials
and methods
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compared with control agents. Petamcin-A was active
against both prokaryotic and eukaryotic microorganisms.
The preparation was more effective against tested gram-
positive bacteria than gram-negative ones (see Table 1).
MICs of Petamcin-A and 12 % acetic acid against
S. aureus and E. coli were determined (Table 2).
Petamcin-A maintained its activity against S. aureus till 14
μl ml−1 concentration, while its MIC for E. coli was 18 μl
ml−1. MICs of 12 % acetic acid were higher-33 μl ml−1 and
50 μl ml−1 for E. coli and S. aureus, respectively.
The results demonstrated the bactericidal activity of
Petamcin-A against almost all tested bacterial strains, with
the exception of B. subtilis WT-A1, against which the ac-
tivity was bacteriostatic. Moreover, Petamcin-A retained
bactericidal activity against S. aureus till 33 μl ml−1 con-
centration (Table 3). In case of E. coli, bactericidal activity
of the preparation was observed till 100 μl ml−1 concentra-
tion. Even though 12 % acetic acid showed bactericidal ac-
tivity too, it lost this activity started from 200 μl ml−1
concentration. This could testify that in low concentrationsTable 2 Determination of MICs of Petamcin-A and 12 % acetic
acid against some test strainsa
Strains MIC, μl ml−1
Petamcin-A Acetic acid
S. aureus 14 33
E. coli 18 50
D. hansenii 25 67
T. viride 15 25
aAll experiments were independently repeated three times. Mean values with
standard deviations are presented, p ≤ 0.0023. For details, see Materials and
methodsof Petamcin-A its component acetic acid is not the main
cause of its bactericidal studies showed that Petamcin-A
had higher activity against all tested yeast strains compared
with control agents. It demonstrated maximal activity
against D. hansenii (see Table 1). Moreover, Petamcin-A
had fungicidal effect against all tested yeast strains and lost
this activity starting from 100 μl ml−1 concentration
against Candida strains, and from 50 μl ml−1 concentra-
tion against D. hansenii. Chlorhexidine and nystatin also
expressed fungicidal activity against tested yeast strains,
whereas 12 % acetic acid showed only static activity against
C. albicans, but was fungicidal against C. guilliermondii
and D. hansenii.
The investigations of anti-mould activity showed that
both Petamcin-A and acetic acid inhibited the germination
of all tested mould spores till 50 μl ml−1 concentration.
However, determination of MIC against T. viride showed
that Petamcin-A inhibited spore germination even at
10 μl ml−1 concentration, whereas 12 % acetic acid MIC
for T. viride spores was 20 μl ml−1.Table 3 Determination of MBCs of Petamcin-A and 12 % acetic
acid against some test strainsa
Strains MBC, μl ml−1
Petamcin-A Acetic acid
S. aureus 33 67
E. coli 100 200
C. albicans 100 –
C. guilliermondii 100 Undiluted
D. hansenii 50 Undiluted
aAll experiments were independently repeated three times. Mean values with
standard deviations are presented, p ≤ 0.002. For details, see Materials and
methods
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against T4 phage of E. coli C-T4 completely inhibiting its
growth. 12 % acetic acid also expressed anti-phage activity,
but with less efficiency (Fig. 1). It caused only 2.4 Log10
reduction of phage units. 200 μl ml−1 concentration of
Petamcin-A also demonstrated considerable activity
reducing phage numbers by 2.6 Log10, while the use of
100 μl ml−1 concentration of 12 % acetic acid resulted
in only 1.4 Log10 reduction of E. coli C-T4.
Discussion
Petamcin-A is patented as antifungal preparation [14]
for the treatment of various fungal skin infections. Its
active antimicrobial components are acetic acid and
hexamethylentetramine which separately have been used
in various medical applications, including the treatment
of skin infections for a long time [16, 17, 20]. However,
there is no data about their activity when applied
together. Thus, it was very interesting to study the anti-
bacterial and antiviral activity of Petamcin-A as a complex
preparation.
Obtained data showed high efficiency of Petamcin-A
against all tested strains, including bacteria, yeast, moulds
and phages. Studies of antibacterial activity of the prepar-
ation illustrated that it was more effective than its compo-
















200 µl ml-1 undiluted
Fig. 1 Anti-phage activity of Petamcin-A (PA) and 12 % acetic acid
(AC) and their 200 μl ml−1 concentrations against T4 phage of E. coli
C-T4 after 90 min exposure time. Saline solution was used as a negative
control. Concentrations of PFU of T4 phage of E. coli C-T4 were
illustrated with Log10 values. Mean values with standard deviations
are presented, p ≤ 0.005. For details, see Materials and methodswas higher against gram-positive bacteria in comparison
with gram-negative ones. Such a difference was previously
described for acetic acid [21]. At the same time there are
no data indicating such differences for another active com-
ponent of Petamcin-A–formaldehyde, which is released by
decomposition of hexamethylenetetramine in even slightly
acidic environment [22–24]. This allows speculating that
this effect of Petamcin-A may be due to acetic acid.
The results allow to make some assumptions concerning
Petamcin-A’s components activities. Particularly, it was
determined, that in case of gram-negative bacteria growth
inhibition zones by Petamcin-A were bigger than that by
12 % acetic acid (see Table 1). This difference was maximal
(16 mm) for E. coli. Conversely, this difference in case of
gram-positive bacteria was minimal (18 mm) for M. luteus,
while it reached maximal value (27 mm) for S. aureus.
Accordingly, it could be speculated that formaldehyde was
more effective against gram-negative bacteria compared
with gram-positive ones. Such a phenomenon was not
described previously.
It is important to mention that Petamcin-A was particu-
larly active against one of the most common causative
agents of skin infections-S. aureus [25].
Petamcin-A killed all tested bacterial strains, except
B. subtilis WT-A1. Bactericidal activity of the prepar-
ation is due to both acetic acid and formaldehyde. Many
researchers reported about bactericidal activity of acetic
acid and formaldehyde [13, 16, 17, 21, 26]. This means
that both these components are responsible bactericidal
activity of Petamcin-A. Two endospore forming bacteria
were used in the study. Petamcin-A activity against
B. licheniformis WT was bactericidal, whereas it was
bacteriostatic against B. subtilis WT-A1. This may lead
to speculations that there was a difference in the activity
of Petamcin-A against sporulating and non-sporulating
bacterial strains. However, B. subtilis WT-A1 strain was
isolated from heavy metal polluted soils. Some studies
state that genes responsible for heavy metal tolerance
and antibiotic resistance are located in the same plasmid
meaning there is a correlation between these two traits
[27, 28]. Consequently, it can be assumed that B. subtilis
WT-A1 strains have resistance against antimicrobials.
Thus, the reason of Petamcin-A’s only bacteriostatic ac-
tivity may be due to enhanced resistance of a particular
strain, instead of its endospore forming ability. There is no
evidence about acetic acid activity against bacterial spores,
but many authors state about sporocidal activity of
formaldehyde [21, 29, 30]. This affirms that Petamcin-A
possesses activity against spores.
Petamcin-A showed high antifungal activity against
tested three yeast and five mould strains. MIC determin-
ation of Petamcin-A and 12 % acetic acid against T. viride
demonstrated that both active components of the pre-
paration have their contribution in antifungal activity.
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antifungal activity of acetic acid even at low concentrations
against Aspergilus flavus, Aspergilus luchuensis, Mucor spp.,
Penicillium oxalicum etc. was shown [31]. High fungicidal
activity of formaldehyde was also reported [29].
The investigation of anti-phage activity showed that
there was a considerable difference between activity of
Petamcin-A and its component acetic acid. This suggests
that antiviral activity of Petamcin-A is only partially due
to acetic acid and, therefore, formaldehyde also have
noticeable implementation in this activity. According to
literature data acetic acid has been reported to be less
effective against viruses compared with formaldehyde
which has confirmed our results [26, 29]. It was shown
that 6 % acetic acid showed only 0.32 Log10 reduction of
Poliovirus after 5 min exposure time [17].
The mechanisms of Petamcin-A’s antimicrobial activity
can be derived based on activities of its two components-
acetic acid and formaldehyde. On the other hand, it is
possible that together they could gain some new advanta-
geous properties. Consequently, some further investiga-
tions are needed to understand the mode of Petamcin-A
action as a complex preparation.
It is known, that mechanisms that underlie the activity
of formaldehyde are due to its reactions with proteins
and nucleic acids [29, 32]. Particularly, it alkylates amino
and sulfhydryl groups of proteins, as well as nitrogen
atoms of the purine rings of nucleic acids [32]. There-
fore, this component is active against almost all types of
microorganisms.
The modes of action of another active component of
Petamcin-A-acetic acid against microbes have not been
understood completely yet. But it is assumed that mainly
its undissociated forms are responsible for antimicrobial
activity [33, 34]. They could passively cross the cell wall
and dissociate at neutral pH within the cells. This brings
to a decrease of internal pH and cause further inhibitory
effects on microbes. For example, interior acidic pH
causes denaturation of acid-sensitive proteins and DNA,
consumption of energy during regulation of internal pH,
etc. It has also been proposed that acetic acid brings to
interruption of the action of bacterial proton pumps
responsible for ion regulation [33, 34].
The main part of this work was done using laboratory
control strains. It would be interesting to investigate
Petamcin-A’s activity against more clinical isolates and
human pathogenic strains. This will be the next step of
the work which could help to broaden its potential
applications.
Concluding remarks
Petamcin-A has a high antimicrobial activity against all
tested bacterial, yeast and mould strains. The preparation
also exhibited high anti-phage activity. Furthermore, takinginto account that Petamcin-A has not shown observable
toxicity on skin and its components are not expensive, it
can be advantageous for management of various skin
medical conditions.
As far as Petamcin-A expressed antimicrobial activity
against various groups of microorganisms, it also may
have perspective to be used as a disinfectant but further
investigations are needed.
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